The potential of histone deacetylase inhibitors for the treatment of multiple myeloma.
Preclinical evidence supports the investigation of histone deacetylase inhibitors for the treatment of myeloma. Results from early studies demonstrate clinical activity and further studies investigating combination strategies should be explored.